Table 3.
Effect of CETPi on lipids
| LDL-C (mg/dL) | HDL-C (mg/dL) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Drug | Arm (n) | Baseline (SD) | >1 year (SD) | Change from baseline (%) | Baseline (SD) | >1 year (SD) | Change from baseline (%) | |||||||||
| CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi-Placebo (%) | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi-Placebo (%) | ||
| ILLUMINATE9 | Torcetrapib | 7533 | 7534 | 79.7 (20.4) | 79.9 (20.4) | NR | NR | –24.9 | 3.0 | –27.9%† | 48.6 (12.0) | 48.5 (12.2) | NR | NR | 72.1 | 1.8 | 70.3%† |
| Dal-OUTCOMES12 | Dalcetrapib | 7938 | 7933 | 76.4 (26.4) | 75.8 (25.9) | NR | NR | NR | NR | 0.0% | 42.5 (11.7) | 42.2 (11.5) | 58.6 (NR) | 46.1 (NR) | 40.0 | 11.0 | 29%† |
| ACCELERATE10 | Evacetrapib | 6038 | 6054 | 81.6 (28.4) | 81.1 (27.8) | 54.7 (26.4) | 83.7 (30.8) | –31.1 | 6.0 | –37.1% | 45.3 (11.7) | 45.3 (11.7) | 104.1 (31.4) | 45.6 (12.3) | 133.2 | 1.6 | 131.6% |
| REVEAL8 | Anacetrapib | 15225 | 15224 | 61 (15) | 61 (15) | 38 (NR) | 64 (NR) | NR | NR | –41.0% | 40 (NR) | 40 (NR) | 85 (NR) | 42 (NR) | NR | NR | 104.0% |
| DEFINE11 | Anacetrapib | 811 | 812 | 81.2 (21.3) | 82.2 (20.7) | 48.9 (NR) | 76.7 (NR) | –40.5 | –4.3 | –36.2% | 40.5 (9.3) | 40.4 (9.1) | 102.3 (NR) | 44.9 (NR) | 151.1 | 12.3 | 138.8% |
*ACCELERATE only reported lipid levels at 3 months.
†Calculated based on available data.